Cullinan Therapeutics, Inc. (NASDAQ: CGEM)
$12.2500
-0.6500 ( -4.89% ) 79.8K
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Market Data
Open
$12.2500
Previous close
$12.9000
Volume
79.8K
Market cap
$751.14M
Day range
$10.3300 - $13.2050
52 week range
$9.9100 - $30.1886
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 27, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
8-k | 8K-related | 48 | Jun 03, 2024 |
8-k | 8K-related | 12 | May 23, 2024 |
4 | Insider transactions | 1 | May 23, 2024 |
def | Proxies and info statements | 4 | May 16, 2024 |
3 | Insider transactions | 2 | May 16, 2024 |
ars | Annual reports | 1 | May 16, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |
10-q | Quarterly Reports | 62 | May 15, 2024 |